Urinary 8-isoprostane is Elevated in Acute Childhood Asthma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01472471

Enrollment

Registered

2011-11-16

Start date

2010-11-30

Completion date

2012-02-29

Last updated

2013-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Asthma, Oxidative Stress

Keywords

Childhood Asthma, Oxidative stress, Urinary 8-isoprostane

Brief summary

Oxidative stress is seen in children with asthma, but is hard to measure. The investigators exploring the utility of using a commercially available assay to measure oxidative stress in the urine in asthmatics. Additionally, the investigators will attempt to prove that oxidative stress is higher in children with acute asthma compared to those with stable asthma and that this stress is also higher in children with more severe clinical asthma exacerbations compared to less severe ones.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

4 Years to 18 Years

Healthy volunteers

Inclusion criteria

Group 1 1. Patients aged 4-18 years 2. Known stable asthmatics on no medications or with no medication changes in 3 weeks prior to enrollment 3. No asthma hospitalizations in past 3 months 4. Parent available to consent Group 2 1. Patients aged 4-18 2. Known asthmatic, admitted to Stony Brook University Hospital for status asthmaticus 3. Parent available to consent

Exclusion criteria

1. Any child with documented fever within 24 hours of study entry 2. Any child with a known current history of tracheo- or bronchomalacia 3. Any child with known clinical or laboratory evidence of shock (see below) 4. Any child with history of documented immunodeficiency, rheumatologic disease, cystic fibrosis, or renal dysfunction (see below) 5. Any child with a current or recent (less than 1 year) history of tracheostomy 6. Any child with a known genetic abnormality 7. Any pregnant child 8. Any child with a history of autism 9. Any child whose parent/caregiver is unable to give informed consent

Design outcomes

Primary

Measure	Time frame
We expect to see increased urinary 8-isoprostane in acute pediatric asthmatics	Urinary 8-isoprostane levels were measured at the end of subject recruitment

Secondary

Measure	Time frame
We expect urinary 8-isoprostane levels to be higher with increased pediatric asthma severity.	This was calculated at the end of patient recruitment, after urinary 8-isoprostane levels were obtained

Countries

United States

Outcome results